05.14.18
Provention Bio has selected Netherlands-based Intravacc to Lead product development and manufacturing of clinical trial material for Provention's coxsackievirus B (CVB) Vaccine (PRV-101). France-based L2D Services SARL/Leads-To-Development (L2D) is providing development, regulatory and project management support to ensure rapid progress of PRV-101 into clinical development.
CVB, an enterovirus, has been identified as a possible common trigger for type 1 diabetes (T1D) onset. Vaccination of at-risk populations against CVB infection may lead to the prevention or delay in onset of T1D. The CVB vaccine was developed initially by Vactech of Finland and licensed to Provention in April, 2017. Provention is planning to initiate first in-human Clinical Trials in 2020.
Provention, in partnership with Intravacc, Vactech and L2D is now developing its CVB vaccine for large scale manufacture of clinical trial material in accordance with current Good Manufacturing Practices ( cGMP ). Intravacc was chosen as Provention's manufacturing partner based on its expertise and track in enterovirus vaccine development, including IPV, sIPV, EV-71, and CV-A16, as well as Intravacc's state-of-the-art vaccine cGMP production facilities. PRV-101 will be developed using Intravacc's proven and well-established platform technology, including certain proprietary Cell Lines and production processes.
"Selecting Intravacc for PRV-101's cGMP production is an important next step in our plan to initiate a potentially transformative clinical program to develop a vaccine to prevent acute coxsackievirus B infection and, ultimately, prevent or delay the onset of as much as half of the world's cases of T1D," said Ashleigh Palmer, co-founder and chief executive officer, Provention BIO . "We welcome this opportunity to work alongside Intravacc, Vactech and L2D to advance our PRV-101 program to the clinic."
Intravacc's chief executive officer, Thijs Veerman, said, "We are very excited to be involved in this project. Intravacc is uniquely positioned to develop cGMP clinical material for this vaccine and ensure its specifications, quality and patient-readiness. We have the necessary knowledge, expertise and experience to advance Provention's PRV-101 program to the next stage and beyond."
CVB, an enterovirus, has been identified as a possible common trigger for type 1 diabetes (T1D) onset. Vaccination of at-risk populations against CVB infection may lead to the prevention or delay in onset of T1D. The CVB vaccine was developed initially by Vactech of Finland and licensed to Provention in April, 2017. Provention is planning to initiate first in-human Clinical Trials in 2020.
Provention, in partnership with Intravacc, Vactech and L2D is now developing its CVB vaccine for large scale manufacture of clinical trial material in accordance with current Good Manufacturing Practices ( cGMP ). Intravacc was chosen as Provention's manufacturing partner based on its expertise and track in enterovirus vaccine development, including IPV, sIPV, EV-71, and CV-A16, as well as Intravacc's state-of-the-art vaccine cGMP production facilities. PRV-101 will be developed using Intravacc's proven and well-established platform technology, including certain proprietary Cell Lines and production processes.
"Selecting Intravacc for PRV-101's cGMP production is an important next step in our plan to initiate a potentially transformative clinical program to develop a vaccine to prevent acute coxsackievirus B infection and, ultimately, prevent or delay the onset of as much as half of the world's cases of T1D," said Ashleigh Palmer, co-founder and chief executive officer, Provention BIO . "We welcome this opportunity to work alongside Intravacc, Vactech and L2D to advance our PRV-101 program to the clinic."
Intravacc's chief executive officer, Thijs Veerman, said, "We are very excited to be involved in this project. Intravacc is uniquely positioned to develop cGMP clinical material for this vaccine and ensure its specifications, quality and patient-readiness. We have the necessary knowledge, expertise and experience to advance Provention's PRV-101 program to the next stage and beyond."
